Novartis signs agreement with TB Alliance for development of its tuberculosis compounds

20 August 2014

Swiss drug major Novartis (NOVN: VX) has signed an exclusive global licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).

Current tuberculosis therapies require dosing regimes of between six and 30 months, and drug-resistant strains are increasingly emerging.

Novartis will fully transfer its tuberculosis research and development program to the TB Alliance, which will take financial and operational responsibility for ongoing research, development, approval and distribution of compounds in the portfolio. One of the compounds is NITD304, which blocks MmpL3, a protein essential for the survival of tuberculosis bacterium.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK